Skip to main content
TipRanks
Go Ultimate75% OFF

Ajooni Biotech Limited (AJOONI) AI Stock Analysis

0 Followers
IN:AJOONI

Ajooni Biotech Limited

(NSE:AJOONI)

Select Model
Rating:60Neutral
Price Target:INR 3.50â–²(11.82% Upside)
Action:reiterated
Date:08/19/26

The overall score reflects a company with strong top-line growth and an improving, modestly leveraged balance sheet offset by structurally weak cash generation and thin, volatile margins, while neutral-to-weak technicals and a broadly middle-of-the-road valuation provide neither a strong upside nor downside signal.

Positive Factors
Revenue GrowthFY2026 revenue rose about 44% after steady prior-year gains, indicating stronger scale and demand across the company’s animal-health and agriculture-adjacent offering. Sustained growth can broaden distribution, improve operating leverage, and create a larger base for future earnings.
Negative Factors
Negative Operating Cash FlowFour consecutive years of negative operating cash flow indicate that reported earnings are not translating reliably into cash from operations. Persistent weak conversion can increase reliance on external funding, limit reinvestment capacity, and make growth more financially demanding over the next several quarters.

Ajooni Biotech Limited (AJOONI) vs. iShares MSCI India ETF (INDA)

-50%-40%-30%-20%-10%0%10%IN:AJOONI-36.64%INDA-5.86%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 539.12M
Dividend Yield
―
Average Volume (3M)
403.46K
Price to Earnings (P/E)
14.1
Beta (1Y)
0.92
Revenue Growth
78.39%
EPS Growth
15.76%
Country
India
Employees
182
Sector
General
Sector Strength
55
Industry
Packaged Foods

Ajooni Biotech Limited Business Overview & Revenue Model

Company Description

Founded in 2010, Ajooni Biotech Limited is an Indian enterprise primarily engaged in the production and distribution of animal nutrition products. Headquartered in Mohali, India, the company's offerings encompass specialized cattle feeds and various...

How the Company Makes Money

Ajooni Biotech Limited primarily makes money by selling animal health and nutrition products (and related livestock/poultry-focused inputs) through its sales and distribution channels to customers in the animal husbandry ecosystem (e.g., farms, distr...

Ajooni Biotech Limited Financial Statement Overview

Summary

Strong revenue growth and a strengthening, low-leverage balance sheet support a solid score, but thin and volatile margins and persistently weak, negative cash flows materially constrain the financial quality.

Income Statement

73Positive

Balance Sheet

78Positive

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue2.15B1.82B1.15B801.15M744.88M740.38M
Gross Profit303.98M276.71M138.13M97.65M87.45M100.24M
EBITDA76.80M62.56M57.57M44.27M30.60M31.12M
Net Income39.59M43.22M32.38M21.61M11.25M10.49M
Balance Sheet
Total Assets1.25B1.20B950.51M475.20M587.31M290.18M
Cash, Cash Equivalents and Short-Term Investments3.74M4.19M68.30M4.30M4.93M573.86K
Total Debt269.11M177.63M19.40M21.68M51.77M53.50M
Total Liabilities332.86M291.74M69.72M48.12M170.62M126.35M
Stockholders Equity916.23M911.91M880.79M427.08M416.69M163.82M
Cash Flow
Free Cash Flow18.31M-232.32M-192.16M-95.54M-84.39M15.60M
Operating Cash Flow135.46M-52.03M-171.84M-39.52M-55.79M36.84M
Investing Cash Flow-122.77M-170.31M-171.34M76.37M-158.24M-18.97M
Financing Cash Flow71.88M158.23M248.26M-35.66M216.55M-19.73M

Ajooni Biotech Limited Technical Analysis

Technical Analysis SentimentNeutral
Last Price3.13

Price Trends

50DMA3.14Negative
100DMA3.50Negative
200DMA3.88Negative

Market Momentum

MACD-0.05Negative
RSI58.25Neutral
STOCH38.89Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AJOONI, the sentiment is Neutral. The current price of 3.13 is above the 20-day moving average (MA) of 2.93, below the 50-day MA of 3.14, and below the 200-day MA of 3.88, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 58.25 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:AJOONI.

Ajooni Biotech Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:AJOONI against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:AVANTIFEEDIN:AVANTIFEED71OutperformINR 101.76B22.03―1.34%8.99%-27.78%
IN:SKMEGGPRODIN:SKMEGGPROD70OutperformINR 12.12B11.59―0.54%21.31%89.98%
IN:PARAGMILKIN:PARAGMILK63NeutralINR 41.56B32.80―0.33%13.13%-10.08%
IN:MUKKAIN:MUKKA61NeutralINR 7.97B10.04――84.77%67.73%
IN:AJOONIIN:AJOONI60NeutralINR 567.29M14.10――78.39%15.76%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:MKPLIN:MKPL47NeutralINR 1.46B31.14――17.76%-50.16%

* General Sector Average

Performance Comparison

-50%0%50%IN:AJOONIIN:AVANTIFEEDIN:MKPLIN:MUKKAIN:PARAGMILKIN:SKMEGGPRODDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:AJOONI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:AJOONIAjooni Biotech Limited3.13-1.90-37.77%
IN:AVANTIFEEDAvanti Feeds Limited746.85-9.23-1.22%
IN:MKPLM K Proteins Limited3.89-2.62-40.25%
IN:MUKKAMukka Proteins Limited26.580.441.68%
IN:PARAGMILKParag Milk Foods Ltd.331.10-18.98-5.42%
IN:SKMEGGPRODSKM Egg Products Export (India) Ltd.230.2017.068.00%

Ajooni Biotech Limited Corporate Events

Ajooni Biotech Confirms SEBI-Compliant Corporate Website Now Fully Functional

Oct 19, 2026

Ajooni Biotech Limited has notified the National Stock Exchange of India that its corporate website has been updated and is now fully functional in line with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 13, 2026